Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma

Molecular Therapy

Volumn 17, Issue 8, 2009, Pages 1387-1394

  Hadchity, Elie ^a   Aloy, Marie Thérèse ^a   Paulin, Christian ^a,b,c   Armandy, Emma ^a   Watkin, Emmanuel ^a,d   Rousson, Robert ^a,b,e   Gleave, Martin ^f   Chapet, Olivier ^a,b,g   Rodriguez Lafrasse, Claire ^a,b,h  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c Service d'anatomie et cytologie pathologiques   (France)

^d UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^e Centre de Biologie Est   (France)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g Service de Radiothérapie   (France)

^h Laboratoire de Biologie des Tumeurs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLUTATHIONE; HEAT SHOCK PROTEIN 27; OGX 427; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GAMMA IRRADIATION; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RADIATION DOSE; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA;

MUS;

EID: 68249119157     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.90     Document Type: Article

References (44)

1. Bourhis, J, Etessami, A and Lusinchi, A (2005). New trends in radiotherapy for head-and-neck-cancer. Ann Oncol 16(Suppl 2): Ii255-ii257.
2. Miyake, H, Muramaki, M, Kurahashi, T, Yamanaka, K, Hara, I and Fujisawa, M (2006). Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anticancer Res 26:1583-1587.
3. Thanner, F, Sütterlin, MW, Kapp, M, Rieger, L, Morr, AK, Kristen, P et al. (2005). Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 25:1649-1653.
4. Kapranos, N, Kominea, A, Konstantinopoulos, PA, Savva, S, Artelaris, S, Vandoros, G et al. (2002). Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 128:426-432.
5. Lebret, T, Watson, RW, Molinié, V, O'Neill, A, Gabriel, C, Fitzpatrick, JM et al. (2003). Heat shock proteins HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma. Cancer 98 970-977.
6. Lo, WY, Tsai, MH, Tsai, Y, Hua, CH, Tsai, FJ, Huang, SY et al. (2007). Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 376:101-107.
7. Storm, FK, Mahvi, DM and Gilchrist, KW (1996). Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 3:570-573.
8. Romani, AA, Crafa, P, Desenzani, S, Graiani, G, Lagrasta, C, Sianesi, M et al. (2007). The expression of Hsp27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma. BMC Cancer 7:232.
9. Vargas-Roig, LM, Gago, FE, Tello, O, Aznar, JC and Ciocca, DR (1998). Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79 468-475.
10. Kassem, HSh, Sangar, V, Cowan, R, Clarke, N and Margison, GP (2002). A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 101:454-460.
11. Teimourian, S, Jalal, R, Sohrabpour, M and Goliaei, B (2006). Down-regulation of Hsp27 radiosensitizes human prostate cancer cells. Int J Urol 13:1221-1225.
12. Préville, X, Salvemini, F, Giraud, S, Chaufour, S, Paul, C, Stepien, G et al. (1999). Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate-dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp Cell Res 247:61-78.
13. Alphonse, G, Aloy, MT, Broquet, P, Gerard, JP, Louisot, P, Rousson, R et al. (2002). Ceramide induces activation of the mitochondrial/ caspases pathway in Jurkat and SCC61 cells sensitive to γ-radiation but activation of this sequence is defective in radioresistant SQ20B cells. Int J Radiat Biol 78:821-835.
14. Aloy, MT, Hadchity, E, Bionda, C, Diaz-Latoud, C, Claude, L, Rousson, R et al. (2008). Protective role of Hsp27 protein against γ radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int J Radiat Oncol Biol Phys 70:543-553.
15. Rane, MJ, Pan, Y, Singh, S, Powell, DW, Wu, R, Cummins, T et al. (2003). Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278: 27828-27835.
16. Wu, R, Kausar, H, Johnson, P, Montoya-Durango, DE, Merchant, M and Rane, MJ (2007). Hsp27 regulates Akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to Akt signal complex. J Biol Chem 282:21598-21608.
17. Osaki, M, Oshimura, M and Ito, H (2004). PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9:667-676.
18. Havasi, A, Li, Z, Wang, Z, Martin, JL, Botla, V, Ruchalski, K et al. (2008). Hsp27 inhibits Bax activation and apoptosis via a PI3 kinase-dependent mechanism. J Biol Chem 283:12305-12313.
19. Rogalla, T, Ehrnsperger, M, Preville, X, Kotlyarov, A, Lutsch, G, Ducasse, C et al. (1999). Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/ tumor necrosis factor α by phosphorylation. J Biol Chem 274 18947-18956.
20. Bruey, JM, Paul, C, Fromentin, A, Hilpert, S, Arrigo, AP, Solary, E et al. (2000). Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 19 4855-4863.
21. Garrido, C, Gurbuxani, S, Ravagnan, L and Kroemer, G (2001). Heat shock proteins: Endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 286:433-442.
22. Bruey, JM, Ducasse, C, Bonniaud, P, Ravagnan, L, Susin, SA, Diaz-Latoud, C et al. (2000). HSP27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2:645-652.
23. Garrido, C, Bruey, JM, Fromentin, A, Hammann, A, Arrigo, AP and Solary, E (1999). HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13:2061-2670.
24. Pandey, P, Farber, R, Nakazawa, A, Kumar, S, Bharti, A, Nalin, C et al. (2000). Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 19 1975-1981.
25. Paul, C, Manero, F, Gonin, S, Kretz-Remy, C, Virot, S and Arrigo, AP (2002). Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 22:816-834.
26. Charrette, SJ, Lavoie, JN, Lambert, H and Landry, J (2000). Inhibition of Daxxmediated apoptosis by heat shock protein 27. Mol Cell Biol 20:7602-7612.
27. Latchman, DS (2005). HSP27 and cell survival in neurones. Int J Hyperthermia 21:393-402.
28. Houlden, H, Laura, M, Wavrant-De Vrièze, F, Blake, J, Wood, N and Reilly, MM (2008). Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 71 1660-1668.
29. Rocchi, P, So, A, Kojima, S, Signaevsky, M, Beraldi, E, Fazli, L et al. (2004). Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64:6595-6602.
30. Rocchi, P, Beraldi, E, Ettinger, S, Fazli, L, Vessella, RL, Nelson, C et al. (2005). Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65:11083-11093.
31. Zoubeidi, A, Zardan, A, Beraldi, E, Fazli, L, Sowery, R, Rennie, P et al. (2007). Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67:10455-10465.
32. Piotrowicz, RS, Martin, JL, Dillman, WH and Levin, EG (1997). The 27-kDa heat shock protein facilitates basic fibroblast growth factor release from endothelial cells. J Biol Chem 272:7042-7047.
33. Pore, N, Gupta, AK, Cerniglia, GJ, Jiang, Z, Bernhard, EJ, Evans, SM et al. (2006). Nelfinavir down-regulates hypoxia-inducible factor 1α and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Res 66: 9252-9259.
34. Zhang, Y and Shen, X (2007). Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 13:2855-2864.
35. Kamada, M, So, A, Muramaki, M, Rocchi, P, Beraldi, E and Gleave, M (2007). Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 6:299-308.
36. Rödel, F, Frey, B, Leitmann, W, Capalbo, G, Weiss, C and Rödel, C (2008). Survivin antisense-oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71:247-255.
37. LaCasse, EC, Cherton-Horvat, GG, Hewitt, KE, Jerome, LJ, Morris, SJ, Kandimalla, ER et al. (2006). Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 12 5231-5241.
38. Yip, KW, Mocanu, JD, Au, PY, Sleep, GT, Huang, D, Busson, P et al. (2005). Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11:8131-8144.
39. Piro, LD (2004). Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology 18:5-10.
40. Gleave, ME and Monia, BP (2005). Antisense therapy for cancer. Nat Rev Cancer 5:468-479.
41. Chi, KN, Siu, LL, Hirte, H, Hotte, SJ, Knox, J, Kollmansberger, C et al. (2008). A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14:833-839.
42. Weichselbaum, RR, Dahlberg, W, Beckett, M, Karrison, T, Miller, D, Clark, J et al. (1986). Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head-and-neck-cancer patients. Proc Natl Acad Sci USA 83 2684-2688.
43. Rodriguez-Lafrasse, C, Alphonse, G, Broquet, P, Aloy, MT, Louisot, P and Rousson, R (2001). Temporal relationships between ceramide production, caspase activation and mitochondrial dysfunction in cell lines with varying sensitivity to anti-Fas-inducedapoptosis. Biochem J 357 407-416.
44. Alphonse, G, Bionda, C, Aloy, MT, Ardail, D, Rousson, R and Rodriguez-Lafrasse, C (2004). Overcoming resistance to γ-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 23:2703-2715.